The drug maker has secured a tentative approval from the US drug regulator to market Brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg.
Brivaracetam is used to treat partial-onset of seizures (epilepsy). The drug will be manufactured at the Zydus Cadila group s formulation manufacturing facility at the SEZ, Ahmedabad (Gujarat).
The group currently received 319 approvals and has filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. The announcement was made before market hours today, 14 June 2021.
On a consolidated basis, the drug maker s net profit surged 76.9% to Rs 731.60 crore on 3.6% increase in net sales to Rs 3,756.20 crore in Q4 March 2021 over Q4 March 2020.
Read more about Zydus Cadila receives USFDA tentative approval for Brivaracetam Tablets on Business Standard. The drug will be manufactured at the group s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Read more about Zydus Cadila receives USFDA tentative approval for Osimertinib Tablets on Business Standard. Osimertinib is used to treat lung cancer. It belongs to a class of drugs known as kinase inhibitors. Osimertinib works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some
Read more about Cadila Healthcare gets USFDA nod for lung cancer drug on Business Standard. The drug major has received tentative approval from the US drug regulator to market osimertinib tablets in the strengths of 40 mg and 80 mg.
Read more about Cadila Healthcare gets USFDA nod Fluphenazine Hydrochloride Tablets on Business Standard. Cadila Healthcare has received final approval from the USFDA to market Fluphenazine Hydrochloride Tablets in the strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg.